A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional)).

Trial Profile

A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional)).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors LIDDS
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Nov 2017 According to a LIDDS media release, recruitment rate of patients has increased as more trial centers have been included in the plan.
    • 31 Aug 2017 According to a LIDDS media release, the Canadian Medicines Agency has approved the study protocol for this clinical study. Screening of patients have been completed and the first patients have been treated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top